MRUS
Merus N.v.
A Dutch biotech company developing antibody therapies for cancer, it engineers full-length human antibodies that latch onto two or more disease targets at once, using its Biclonics® and Triclonics® platforms. Founded in 2003 in Utrecht by a team of scientists including antibody expert Ton Logtenberg, the firm takes its name from the Latin word "merus," meaning pure or unmixed—a nod to the clean, natural design of its antibody molecules.
CINS: N5749R100HealthcareNL1 holder